登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《NEJM，5月7日，Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-05-08

  • Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

    List of authors.

    Joshua Geleris, M.D., Yifei Sun, Ph.D., Jonathan Platt, Ph.D., Jason Zucker, M.D., Matthew Baldwin, M.D., George Hripcsak, M.D., Angelena Labella, M.D., Daniel Manson, M.D., Christine Kubin, Pharm.D., R. Graham Barr, M.D., Dr.P.H., Magdalena E. Sobieszczyk, M.D., M.P.H., and Neil W. Schluger, M.D.

    May 7, 2020

    DOI: 10.1056/NEJMoa2012410

    Abstract

    BACKGROUND

    Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use.

    METHODS

    We examined the association between hydroxychloroquine use and intubation or death at a large medical center in New York City. Data were obtained regarding consecutive patients hospitalized with Covid-19, excluding those who were intubated, died, or discharged within 24 hours after presentation to the emergency department (study baseline). The primary end point was a composite of intubation or death in a time-to-event analysis. We compared outcomes in patients who received hydroxychloroquine with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score.

  • 原文来源：https://www.nejm.org/doi/full/10.1056/NEJMoa2012410?query=featured_coronavirus
98浏览量
原文链接
相关报告

  • 《MedRxiv，5月25日，Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-05-26
    • Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study View ORCID ProfileAndrew Ip, View ORCID ProfileDonald A Berry, Eric Hansen, View ORCID ProfileAndre H Goy, Andrew L Pecora, Brittany A Sinclaire, Urszula Bednarz, Michael Marafelias, Scott M Berry, Nicholas S Berry, Shivam Mathura, Ihor S Sawczuk, Noa Biran, View ORCID ProfileRonaldo C Go, Steven Sperber, Julia A Piwoz, Bindu Balani, Cristina Cicogna, Rani Sebti, Jason Zuckerman, Keith M Rose, Lisa Tank, Laurie Jacobs, Jason Korcak, Sarah L Timmapuri, Joseph P Underwood III, Gregory Sugalski, Carol Barsky, Daniel W Varga, Arif Asif, Joseph C Landolfi, View ORCID ProfileStuart L Goldberg doi: https://doi.org/10.1101/2020.05.21.20109207 Abstract Background: Hydroxychloroquine has been touted as a COVID-19 treatment. Tocilizumab, an inhibitor of IL-6, has been proposed as a treatment of critically ill patients. Objective: To describe the association between mortality and hydroxychloroquine or tocilizumab therapy among hospitalized COVID-19 patients. Design: Retrospective observational cohort study of electronic health records Setting: 13-hospital network spanning the state of New Jersey. Participants: Patients hospitalized between March 1, 2020 and April 22, 2020 with positive polymerase chain reaction results for SARS-CoV-2. Follow up was through May 5, 2020. Main Outcomes: The primary outcome was death. Results: Among 2512 hospitalized patients with COVID-19 there have been 547 deaths (22%), 1539 (61%) discharges and 426 (17%) remain hospitalized. 1914 (76%) received at least one dose of hydroxychloroquine and 1473 (59%) received hydroxychloroquine with azithromycin. After adjusting for imbalances via propensity modeling, compared to receiving neither drug, there were no significant differences in associated mortality for patients receiving any hydroxychloroquine during the hospitalization (HR, 0.99 [95% CI, 0.80-1.22]), hydroxychloroquine alone (HR, 1.02 [95% CI, 0.83-1.27]), or hydroxychloroquine with azithromycin (HR, 0.98 [95% CI, 0.75-1.28]). *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    86浏览量
    原文链接

  • 《Med，6月5日，Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-06-06
    • Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19 Author links open overlay panelJosephMagagnoliMS12∗SiddharthNarendranMD45∗FelipePereiraMD45∗Tammy H.CummingsPhD12James W.HardinPhD3S. ScottSuttonPharmD12JayakrishnaAmbatiMD4567 Show more https://doi.org/10.1016/j.medj.2020.06.001 Abstract Background Despite limited and conflicting evidence, hydroxychloroquine, alone or in combination with azithromycin, is widely used in COVID-19 therapy. Methods We performed a retrospective study of electronic health records of patients hospitalized with confirmed SARS-CoV-2 infection in United States Veterans Health Administration medical centers between March 9, 2020 and April 29, 2020. Patients hospitalized within 24 hours of diagnosis were classified based on their exposure to hydroxychloroquine alone (HC) or with azithromycin (HC+AZ) or no HC as treatments. The primary outcomes were mortality and use of mechanical ventilation.
    64浏览量
    原文链接